Home
overview

SMi is proud to announce the latest conference in its Pricing & Reimbursement series. Building on the success of our previous events, this exciting conference will provide attendees with a complete view of the pricing and market access fields. Focusing on the development of novel pricing and market access strategies, this informative conference will bring together key opinion leaders in the field to provide attendees with an in depth look into current advances in pharmaceutical pricing and reimbursement.

With the current global economic crisis and rising healthcare costs, European Governments have taken cautious approaches towards pricing and reimbursement (P&R) for pharmaceuticals. and with the constant aging and expanding of populations across Europe, improving standards of living has meant there has been a significant burden on the healthcare systems. This event will explore how companies can overcome these issues and understand the current status of emerging markets and their impact on international healthcare.

With senior industry representatives presenting on their own experiences and referring to case studies, success stories and failures, this event promises to be a unique forum for problem-solving debate and idea-sharing discussion.

This long established event, now in its 18th year, will bring together a unique group of people to discuss the key developments in the field. With speakers from all over Europe and further afield this event will be the perfect platform to share knowledge, debate the latest pricing systems across the EU and evaluate price referencing strategies.

Learn about the benefits and obstacles when collaborating with HTAs

Discuss market access strategies for Orphan Drugs

Consider developments in the pricing of biosimilars and biobetters

Understand the consequences of Germany's AMNOG

Debate the importance and success rates of risk sharing agreements

Evaluate current strategies for pricing and reimbursement in emerging markets

Develop ideas and network with key industry professionals

SMi's 18th annual European Pharmaceutical Pricing & Reimbursement Conference will build on the success of our previous events and bring together a unique mix of senior executives from the industry, academia and the public sector and will provide an unrivalled forum for problem-solving discussion and debate.

This event should be attended by Chief Executives, Chief Scientific Officers, Vice Presidents, Heads, Directors, Principal Scientists and Managers in the following areas:

• Market Access
• Launch Excellence
• Pricing and Reimbursement
• Marketing (Consumer, Relationship, Multi channel,Strategic)
• Project Management
• Value Based Pricing
• Business Development
• Patient Advocacy
• Medical Information & Education
• CRM
• Business Analysis
• eMarketing
• Pharmacy Operations
• Specialty and Orphan drugs market
• Patient communications
• Health economics and outcomes research
• External affairs

Last year's Pricing and Reimbursement Conferences included Senior Representatives from:
Acorda Therapeutics Inc; Allergy Therapeutics Ltd; Basilea Pharmaceutica; Basilea Pharmaceutica Ltd; Baxter ; Boston Healthcare Associates; Celgene Europe Ltd; German Association of Research-Based Pharmaceutical Companies; Gilead Sciences Ltd; IDIS; IGES Institut.; IHS Global Insight; IMS Health; Inpharmation ; Ituah Hospital; Johnson & Johnson Ethicon; JustPharmaReports; Kowa Pharmaceuticals Europe Company Ltd; Medical University of Lublin; Mulago Hospital; Neuro Search A / S; Novartis; Novartis International AG; Novartis Pharma AG; Novartis Pharma GmbH; Office Of Health Economics; PDCI Market Access Inc. ; PIMESP; Roche; Roche Chemische Unternehmungen AG; Santhera Pharmaceuticals; Shire Pharmaceuticals Group Plc; Takeda; Temas Srl; UCB Pharma; Vifor Pharma; White and Case;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Neil Palmer

Neil Palmer, President and Principal Consultant, PDCI Market Access Inc.

9:10 Evolution of pricing and reimbursement strategies in oncology

Uday Bose

Uday Bose, EMEA, Oncology Business Unit Head, Eisai Europe Ltd

  • Review the payer and pharma perspective with respect to pricing and reimbursement
  • Examine key evolutions in how payers have been assessing oncology products
  • Review and critique of case studies
  • Describe potential changes moving forward and steps Pharma should consider to prepare
  • 9:50 Can talking to payers (or ex-payers) do more harm than good?

    Gary Johnson

    Gary Johnson, Managing Director, Inpharmation

  • The ritual of talking to a small number of ex-payers, advisers to payers etc. to investigate how a novel pharmaceutical could be priced is well established.  But does it work?
  • Do payers "game" and deliberately mislead?
  • Do payers all think the same way?  And if not, does talking to a very small number of people introduce huge sampling error?
  • Does what payers say relate to what they actually do?  And, if not, could we just analyse their behaviour?
  • 10:30 Morning Coffee

    11:00 Trends in HTA - What is happening where?

  • An analysis from the Quintiles HTA Watch comparing actual assessments and decisions from leading HTA agencies
  • Update on GB-A and IQWiG decisions - how do these compare with other HTA agencies?
  • Use of PROs - to what extent can these influence decisions?
  • Janice Haigh

    Janice Haigh, Practice Leader, Market Access, Quintiles (UK) Ltd

    11:40 International Reference Pricing - Avoid Millions in Margin Erosion with Innovative Solutions

    Arnaud Grunwald

    Arnaud Grunwald, Senior Director Strategic Solutions, Model N, Inc.

    12:20 Networking Lunch

    13:50 Survival: The first 2 years of AMNOG

    Stefan Walzer

    Stefan Walzer, General Manager, MArS Market Access & Pricing Strategy UG

  • AMNOG process: Put into stone? Political update
  • AMNOG learning from history: Which were the mistakes you should avoid?
  • Survived! Key tactics for a successful GBA submission and price negotiation
  • 14:30 Effects of the proposed reform of the EU Transparency Directive

    James Killick

    James Killick, Partner, White & Case L L P

  • Overview of the directive and proposed changes
  • The effects of this directive on pricing and reimbursement around Europe
  • The importance of transparency
  • 15:10 Afternoon Tea

    15:30 The impact of Value Based Pricing in the UK

    Leslie Galloway

    Leslie Galloway, Chairman, Ethical Medicines Industry Group

  • VBP – What will it look like?
  • Challenges for the industry
  • Impact on innovation
  • 16:10 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Gary Johnson

    Gary Johnson, Managing Director, Inpharmation

    9:10 Value and patient access considerations: a possible framework for Improving access to rare diseases treatments

    Adam Hutchings

    Adam Hutchings, Partner, GMAS

  • Rare Diseases environment - key facts & features
  • Rare diseases treatments – drivers & challenges for improved patient access
  • Value & patient access considerations for rare diseases treatments:  which possible framework for improved patient access? Options, issues and future directions
  • 10:30 Morning Coffee

    11:00 Canadian Market Access Overview

    Neil Palmer

    Neil Palmer, President and Principal Consultant, PDCI Market Access Inc.

  • Overview of Canadian health care system and pharmaceutical funding
  • Price regulation: impact of the new PMPRB guidelines
  • CADTH/CDR, pCODR, provincial reimbursement schemes & listing (risk sharing) agreements
  • National implications of the Ontario 20% pricing rule for generics
  • Implications of international pricing/reimbursement policy reforms (AMNOG, VBP) on Canada
  • Outlook for Canadian pricing & reimbursement
  • 11:40 Latest changes to P&R in Japan

    Donald Macarthur

    Donald Macarthur, Global Pharmaceutical Business Analyst, JustPharmaReports

  • Launch price setting
  • Price revision
  • Premium for new drug development
  • Promotion of generic use
  • Prospects for Health Technology Assessments
  • 12:20 Networking Lunch

    13:40 Panel Discussion: Market Access Developments: Europe vs Rest of the World

    14:20 Distant Cries: Designing clinical trial needs today for tomorrow’s access and pricing

  • The importance of effective clinical trial design for pricing
  • Advantages in terms of market access
  • Short term effects and long term developments
  • Michael Wang

    Michael Wang, VP, Global Market Access, Grunenthal Gmbh

    Cyrus Chowdhury

    Cyrus Chowdhury, Chief Executive Officer and Managing Director, CB Partners

    15:00 Afternoon Tea

    15:20 Risk-Sharing: Developing a commercial strategy

    Tsveta Milanova

    Tsveta Milanova, Director EMEA Pricing and Market Access, Celgene Ltd

  • How should manufacturers define opportunities for innovating pricing?
  • Orphan Drugs: How are they different?
  • How to weigh challenges and opportunities
  • Innovating pricing in the context of EU P&R reforms
  • 16:30 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Arnaud Grunwald

    Arnaud Grunwald

    Senior Director Strategic Solutions, Model N, Inc.
    Thilo Schaufler

    Thilo Schaufler

    Head of Market Access and Governmental Affairs , Abbott

    Adam Hutchings

    Partner, GMAS
    Adam Hutchings

    Arnaud Grunwald

    Senior Director Strategic Solutions, Model N, Inc.
    Arnaud Grunwald

    Cyrus Chowdhury

    Chief Executive Officer and Managing Director, CB Partners
    Cyrus Chowdhury

    Donald Macarthur

    Global Pharmaceutical Business Analyst, JustPharmaReports
    Donald Macarthur

    Gary Johnson

    Managing Director, Inpharmation
    Gary Johnson

    James Killick

    Partner, White & Case L L P
    James Killick

    Janice Haigh

    Practice Leader, Market Access, Quintiles (UK) Ltd
    Janice Haigh

    Leslie Galloway

    Chairman, Ethical Medicines Industry Group
    Leslie Galloway

    Michael Wang

    VP, Global Market Access, Grunenthal Gmbh
    Michael Wang

    Neil Palmer

    President and Principal Consultant, PDCI Market Access Inc.
    Neil Palmer

    Stefan Walzer

    General Manager, MArS Market Access & Pricing Strategy UG
    Stefan Walzer

    Thilo Schaufler

    Head of Market Access and Governmental Affairs , Abbott
    Thilo Schaufler

    Tomas Dolezal

    Director, IHETA
    Tomas Dolezal

    Tsveta Milanova

    Director EMEA Pricing and Market Access, Celgene Ltd
    Tsveta Milanova

    Uday Bose

    EMEA, Oncology Business Unit Head, Eisai Europe Ltd
    Uday Bose

    Workshops

    Developing International Price Referencing Systems
    Workshop

    Developing International Price Referencing Systems

    Copthorne Tara Hotel
    31st October 2012
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.